ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 133 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 1.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $73,000 | +58.7% | 3,877 | 0.0% | 0.00% | – |
| Q2 2019 | $46,000 | -13.2% | 3,877 | 0.0% | 0.00% | – |
| Q1 2019 | $53,000 | +39.5% | 3,877 | +4.7% | 0.00% | – |
| Q4 2018 | $38,000 | -38.7% | 3,702 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $62,000 | +29.2% | 3,702 | +20.7% | 0.00% | – |
| Q2 2018 | $48,000 | +23.1% | 3,066 | 0.0% | 0.00% | – |
| Q1 2018 | $39,000 | +11.4% | 3,066 | 0.0% | 0.00% | – |
| Q4 2017 | $35,000 | +169.2% | 3,066 | +198.2% | 0.00% | – |
| Q3 2017 | $13,000 | +8.3% | 1,028 | 0.0% | 0.00% | – |
| Q2 2017 | $12,000 | -42.9% | 1,028 | 0.0% | 0.00% | – |
| Q1 2017 | $21,000 | 0.0% | 1,028 | 0.0% | 0.00% | – |
| Q4 2016 | $21,000 | -38.2% | 1,028 | 0.0% | 0.00% | – |
| Q3 2016 | $34,000 | +61.9% | 1,028 | +23.7% | 0.00% | – |
| Q2 2016 | $21,000 | +5.0% | 831 | 0.0% | 0.00% | – |
| Q1 2016 | $20,000 | -25.9% | 831 | 0.0% | 0.00% | – |
| Q4 2015 | $27,000 | +237.5% | 831 | +235.1% | 0.00% | – |
| Q3 2015 | $8,000 | – | 248 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 2,942,130 | $34,629,000 | 11.36% |
| Foresite Capital Management II, LLC | 1,586,220 | $18,670,000 | 10.50% |
| DAFNA Capital Management LLC | 636,013 | $7,486,000 | 2.81% |
| Redmile Group, LLC | 8,244,896 | $97,042,000 | 2.75% |
| Lion Point Capital, LP | 1,204,600 | $14,178,000 | 1.40% |
| Palo Alto Investors LP | 1,861,630 | $21,911,000 | 1.06% |
| SAMLYN CAPITAL, LLC | 3,517,856 | $41,405,000 | 0.87% |
| Bellevue Group AG | 4,118,806 | $48,478,000 | 0.83% |
| Rock Springs Capital Management LP | 1,562,300 | $18,388,000 | 0.66% |
| Artal Group S.A. | 850,000 | $10,005,000 | 0.40% |